Floatz Rating
C39/100
Confidence
Indicative
Sponsor
Peking University
Modality
Cell therapy
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05393986CT.gov Claudin18.2-redirected Chimeric Antigen Receptor T Cells With Co-expression of Cytokines in Solid Tumors | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Gastric Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| ct048 autologous (this asset) | Peking University | P1 | C · 39 |
| Fluorouracilum | Boehringer Ingelheim | P3 | BB |
| Capecitabine | Shanghai Zhongshan Hospital | P3 | BB |
| Trastuzumab | Boehringer Ingelheim | P2 | BB |
| Cis-Diamminedichloroplatinum Ii | Mayo Clinic | P3 | BB |
| Oxaliplatin | Shanghai Zhongshan Hospital | P3 | BB |
| Pembrolizumab | Epkin | P3 | BB |
| Irinotecan | Georgetown University | P3 | B |
| Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer | University of California, Irvine | P2 | B |
+42 more in the Gastric Adenocarcinoma cohort
Other indications for ct048 autologous
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Gastroesophageal Junction Adenocarcinoma | — | P1 | C · 39 |
| Pancreatic Neoplasm | — | P1 | C · 36 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. ct048 autologous in Gastric Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ct048-autologous-gastric-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →